Charlie Hospital Semarang Valuation

Is RSCH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RSCH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RSCH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RSCH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RSCH?

Key metric: As RSCH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RSCH. This is calculated by dividing RSCH's market cap by their current revenue.
What is RSCH's PS Ratio?
PS Ratio	18.7x
Sales	Rp47.74b
Market Cap	Rp890.40b

RSCH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	19.4x
Enterprise Value/EBITDA	142.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RSCH's PS Ratio compare to its peers?

The above table shows the PS ratio for RSCH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.2x
RSGK Kedoya Adyaraya	2.7x	n/a	Rp1.1t
MTMH Murni Sadar	2x	n/a	Rp2.1t
BMHS Bundamedik	1.4x	10.5%	Rp2.2t
SAME Sarana Meditama Metropolitan	2.7x	n/a	Rp4.5t
RSCH Charlie Hospital Semarang	18.7x	n/a	Rp890.4b

Price-To-Sales vs Peers: RSCH is expensive based on its Price-To-Sales Ratio (18.7x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does RSCH's PS Ratio compare vs other companies in the ID Healthcare Industry?

4 Companies	Price / Sales	Estimated Growth	Market Cap
EPMT Enseval Putera Megatrading	0.2x	n/a	US$407.84m
PEVE PT. Penta Valent	0.2x	n/a	US$27.14m
SDPC Millennium Pharmacon International	0.05x	n/a	US$13.32m
ZBRA Dosni Roha Indonesia	0.2x	n/a	US$12.34m

No more companies available in this PS range

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: RSCH is expensive based on its Price-To-Sales Ratio (18.7x) compared to the ID Healthcare industry average (2x).

Price to Sales Ratio vs Fair Ratio

What is RSCH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RSCH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	18.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RSCH's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.